Where I see patients (2)
My reviews
Selected research
-
Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94].
European urology
-
BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.
Blood
-
Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib.
Leukemia
Contact me
- Request appointment
- Refer a patient
- (415) 353-2421
4.9